Pomalidomide and dexamethasone until progression after first salvage therapy in multiple myeloma
暂无分享,去创建一个
P. Moreau | M. Macro | X. Leleu | T. Facon | M. Attal | B. Royer | L. Garderet | F. Kuhnowski | Benoît Berge | M. Roussel | I. Lafon | L. Karlin | A. Perrot | A. Stoppa | C. Chaleteix | M. Tiab | C. Araujo | P. Lenain | K. Belhadj | C. Hulin | H. A. Loiseau | M. Petillon | Souhila Ikhlef | M. Escoffre-barbe | Laure Devlamynck
[1] S. Jagannath,et al. Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma. , 2022, The New England journal of medicine.
[2] G. Morgan,et al. Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] D. Dingli,et al. Impact of maintenance therapy post autologous stem cell transplantation for multiple myeloma in early and delayed transplant , 2022, Bone Marrow Transplantation.
[4] J. Laubach,et al. A phase I/II study of ixazomib, pomalidomide, and dexamethasone for lenalidomide and proteasome inhibitor refractory multiple myeloma (Alliance A061202) , 2021, American journal of hematology.
[5] F. Gao,et al. A single center retrospective study of daratumumab, pomalidomide, and dexamethasone as 2nd-line therapy in multiple myeloma , 2021, Leukemia & lymphoma.
[6] M. Dimopoulos,et al. Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial. , 2021, The Lancet. Oncology.
[7] M. Boccadoro,et al. Dose/Schedule-Adjusted Rd-R vs Continuous Rd for elderly, intermediate-fit, newly diagnosed multiple myeloma patients. , 2021, Blood.
[8] N. Munshi,et al. Early Versus Late Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma: Long-Term Follow-up Analysis of the IFM 2009 Trial , 2020 .
[9] M. Dimopoulos,et al. Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse , 2020, Leukemia.
[10] U. Mellqvist,et al. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 stud , 2020, The Lancet. Haematology.
[11] Versione,et al. Common Terminology Criteria for Adverse Events , 2020, Definitions.
[12] M. Beksac,et al. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study , 2019, The Lancet.
[13] M. Beksac,et al. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial. , 2019, The Lancet. Oncology.
[14] G. Morgan,et al. Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial , 2019, The Lancet. Oncology.
[15] B. Pégourié,et al. Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma. , 2018, Blood.
[16] M. Kersten,et al. Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial , 2018, Leukemia.
[17] Sin-Ho Jung,et al. Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] N. Munshi,et al. Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma , 2017, The New England journal of medicine.
[19] S. Parmar,et al. Prolonged survival with a longer duration of maintenance lenalidomide after autologous hematopoietic stem cell transplantation for multiple myeloma , 2016, Cancer.
[20] G. Morgan,et al. Lenalidomide Is a Highly Effective Maintenance Therapy in Myeloma Patients of All Ages; Results of the Phase III Myeloma XI Study , 2016 .
[21] S. Jagannath,et al. Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma. , 2016, Blood.
[22] Michael L. Wang,et al. Maintenance Therapy With Immunomodulatory Drugs in Multiple Myeloma: A Meta-Analysis and Systematic Review. , 2016, Journal of the National Cancer Institute.
[23] B. Pégourié,et al. Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and/or translocation (4;14): IFM 2010-02 trial results. , 2015, Blood.
[24] B. Barlogie,et al. Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. , 2014, The Lancet. Oncology.
[25] M. Boccadoro,et al. Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study. , 2013, Blood.
[26] M. Beksac,et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. , 2012, The New England journal of medicine.
[27] K. Owzar,et al. Lenalidomide after stem-cell transplantation for multiple myeloma. , 2012, The New England journal of medicine.
[28] B. Pégourié,et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. , 2012, The New England journal of medicine.
[29] M. Beksac,et al. IMWG consensus on maintenance therapy in multiple myeloma. , 2012, Blood.
[30] Serge Leyvraz,et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. , 2006, Blood.
[31] B. Barlogie,et al. International uniform response criteria for multiple myeloma , 2006, Leukemia.
[32] M. Smyth,et al. Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma , 2010, Leukemia.